Fibroblast growth factor receptor promotes progression of cutaneous squamous cell carcinoma
- 29 June 2019
- journal article
- research article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 58 (10) , 1715-1725
Abstract
Cutaneous squamous cell carcinoma (cSCC) is a keratinocyte‐derived invasive and metastatic tumor of the skin. It is the second‐most commonly diagnosed form of skin cancer striking 200 000 Americans annually. Further, in organ transplant patients, there is a 65‐ to 100‐fold increased incidence of cSCC compared to the general population. Excision of cSCC of the head and neck results in significant facial disfigurement. Therefore, increased understanding of the mechanisms involved in the pathogeneses of cSCC could identify means to prevent, inhibit, and reverse this process. In our previous studies, inhibition of fibroblast growth factor receptor (FGFR) significantly decreased ultraviolet B‐induced epidermal hyperplasia and hyperproliferation in SKH‐1 mice, suggesting an important role for FGFR signaling in skin cancer development. However, the role of FGFR signaling in the progression of cSCC is not yet elucidated. Analysis of the expression of FGFR in cSCC cells and normal epidermal keratinocytes revealed protein overexpression and increased FGFR2 activation in cSCC cells compared to normal keratinocytes. Further, tumor cell‐specific overexpression of FGFR2 was detected in human cSCCs, whereas the expression of FGFR2 was low in premalignant lesions and normal skin. Pretreatment with the pan‐FGFR inhibitor; AZD4547 significantly decreased cSCC cell‐cycle traverse, proliferation, migration, and motility. Interestingly, AZD4547 also significantly downregulated mammalian target of rapamycin complex 1 and AKT activation in cSCC cells, suggesting an important role of these signaling pathways in FGFR‐mediated effects. To further bolster the in vitro studies, NOD.Cg‐Prkdcscid Il2rgtm1Wjl/SzJ mice with SCC12A tumor xenografts treated with AZD4547 (15 mg/kg/bw, twice weekly oral gavage) exhibited significantly decreased tumor volume compared to the vehicle‐only treatment group. The current studies provide mechanistic evidence for the role of FGFR and selectively FGFR2 in the early progression of cSCC and identifies FGFR as a putative therapeutic target in the treatment of skin cancer.Keywords
Funding Information
- National Cancer Institute (5R01CA217180)
This publication has 56 references indexed in Scilit:
- FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial‑mesenchymal transition to gefitinibOncology Reports, 2018
- A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplificationAnnals of Oncology, 2017
- Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I studyInvestigational New Drugs, 2017
- Rising incidence and aggressive nature of cutaneous malignancies after transplantation: An update on epidemiology, risk factors, management and surveillanceSurgical Oncology, 2015
- Genomic Analysis of Metastatic Cutaneous Squamous Cell CarcinomaClinical Cancer Research, 2015
- Advances in the management of cutaneous squamous cell carcinomaF1000Prime Reports, 2014
- Apoptosis and Pathogenesis of Melanoma and Nonmelanoma Skin Cancer2008
- The role of fibroblast growth factors and their receptors in prostate cancerEndocrine-Related Cancer, 2004
- Identification of the Tuberous Sclerosis Complex-2 Tumor Suppressor Gene Product Tuberin as a Target of the Phosphoinositide 3-Kinase/Akt PathwayMolecular Cell, 2002
- FGF-10 disrupts lung morphogenesis and causes pulmonary adenomas in vivoAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2001